Sage Therapeutics Inc
(FRA:SG7)
€
6.826
-1.132 (-14.22%)
Market Cap: 365.22 Mil
Enterprise Value: -151.29 Mil
PE Ratio: 0
PB Ratio: 0.72
GF Score: 48/100 SAGE Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023 / 03:30PM GMT
Release Date Price:
€47.8
(+1.70%)
Brian Abrahams
RBC Capital Markets - Analyst
I'm Brian Abrahams, one of the senior biotech analysts at RBC Capital Markets. We're really pleased to have with us our next presenting company, Sage Therapeutics. Obviously, a very eventful time for Sage, so thanks so much for being here. I know you guys are very busy.
Representing Sage, we have their Chief Business Officer, Chris Benecchi; their Chief Financial Officer, Kimi Iguchi; and their Chief Scientific Officer, Al Robichaud. Thank you. Thanks again.
Al Robichaud
Sage Therapeutics, Inc. - Chief Scientific Officer
Thank you.
Kimi Iguchi
Sage Therapeutics, Inc. - CFO
Great.
Questions & Answers
Brian Abrahams
RBC Capital Markets - Analyst
So maybe starting with just what's, I think, on the top of most people's minds, zuranolone and the ongoing review process. Can you give us any sense, maybe generally speaking, on just how the FDA's review process for zuranolone's been going and your sense overall
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot